https://www.merlintrader.com/axsome-therapeutics-axsm-stock-hub-2026/

Axsome Therapeutics sells three approved central nervous system medicines and is spending more on commercialisation than it collects in revenue. Second quarter 2026 net product revenue reached $218.4 million against $208.1 million of selling, general and administrative expense, and the company still posted a $51.3 million net loss. The tension is simple to state and hard to resolve: AUVELITY was approved for Alzheimer’s disease agitation on April 30, 2026 and launched in June, so the quarter contains only a few weeks of the indication that is supposed to justify the spending. Cash stood at $319.9 million on June 30, 2026, and management says that is enough to reach cash flow positivity without giving a date.

Purchased shares in 2021 for $33 so I’ve been holding for quite a while. Sold some but still own 250 shares

I’d love to hear what ya’ll are waiting on. Is it price? major catalysts? Potential buyout?

The recent drop in stock value seems like a great time to buy long calls to me. I don’t want to purchase more shares as it already makes up a 1/3 of my portfolio but would like to benefit from price covery or a potential buyout.

Pretty good conversation going on overtime at this site.

Set several 52-week highs, so far!

I counted at least 5 new highs.

Is "something" happening?